Molecular PharmaceuticsPub Date : 2026-10-05Epub Date: 2026-09-01DOI: 10.1021/acs.molpharmaceut.6c00409
Christian Weinmann, Franz Waibl, Silvan Käser, Fabio Casagrande, Jitao David Zhang, Fabian Dey, Björn Wagner, Britta Schulze, Carsten Kroll, Janneke Keemink
{"title":"DynlogPA Novel High-Throughput LC−MS Assay Quantifying Dynamic Lipophilicity and Chameleonicity of bRo5 Macrocyclic Peptides","authors":"Christian Weinmann, Franz Waibl, Silvan Käser, Fabio Casagrande, Jitao David Zhang, Fabian Dey, Björn Wagner, Britta Schulze, Carsten Kroll, Janneke Keemink","doi":"10.1021/acs.molpharmaceut.6c00409","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00409","url":null,"abstract":"<p>The landscape of drug discovery has expanded beyond the traditional chemical space into the domain of large, flexible molecules, including beyond rule-of-five (bRo5) macrocyclic peptides (MCPs). Molecular chameleonicity, the capacity to dynamically adapt the conformation to the environment, balancing aqueous solubility and membrane permeability, has the potential to improve the oral bioavailability of these compounds. However, we lack experimental methods that quantify chameleonicity in a high-throughput manner. To address this need, we introduce Dynlog<em>P</em>, a novel high-throughput, fully automated assay based on reverse-phase LC−MS that can quantify chameleonicity with minimal compound input. Dynlog<em>P</em> measures calibrated lipophilicity under conditions promoting either solvent hydrogen bonding (log <em>P</em><sub>70</sub>) or intramolecular hydrogen bonding (log <em>P</em><sub>95</sub>), providing a quantitative measure of chameleonicity (Δlog <em>P</em><sub>95−70</sub>) that is validated with NMR and molecular dynamics simulations. We profiled hundreds of molecules with Dynlog<em>P</em> and demonstrate that chameleonicity is a common feature of MCPs. Machine learning models trained with Dynlog<em>P</em> data allow for the prospective prediction of chameleonicity. Adoption and further refinement of Dynlog<em>P</em> have the potential to empower compound prioritization and the design of orally bioavailable MCP-based therapeutics.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 10","pages":"4872–4883"},"PeriodicalIF":4.9,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149093528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular PharmaceuticsPub Date : 2026-10-05Epub Date: 2026-09-07DOI: 10.1021/acs.molpharmaceut.6c00590
Nancy Cham, Allison M. Pataro, Amber Liles, Grace K. Choi, Sophia L. Fischer, Sarah A. Ramadan, Serena X. Gao, Sarah A. Doebley, Oleg G. Chepurny, George G. Holz, Matthew R. Hayes, Bart C. De Jonghe, Robert P. Doyle, Tito Borner
{"title":"A Dicyanocobinamide Conjugate of the GLP-1R Agonist Exendin-4 Improves Glucose Homeostasis in Tumor-Bearing Rats without Exacerbating Anorexia and Weight Loss","authors":"Nancy Cham, Allison M. Pataro, Amber Liles, Grace K. Choi, Sophia L. Fischer, Sarah A. Ramadan, Serena X. Gao, Sarah A. Doebley, Oleg G. Chepurny, George G. Holz, Matthew R. Hayes, Bart C. De Jonghe, Robert P. Doyle, Tito Borner","doi":"10.1021/acs.molpharmaceut.6c00590","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00590","url":null,"abstract":"<p>Cancer anorexia−cachexia syndrome (CACS) is a prevalent and debilitating complication of malignancy, characterized by reduced food intake, loss of skeletal muscle mass, and severe metabolic dysfunction. Insulin resistance and impaired glucose tolerance are prominent features of CACS and contribute to worsened prognosis, yet treatment options that improve metabolic regulation without exacerbating anorexia are limited. Although GLP-1 receptor (GLP-1R) agonists effectively enhance glucose control, their centrally mediated anorectic and aversive effects limit their use in cancer patients. To address this limitation, we developed a peripherally restricted GLP-1R agonist by conjugating exendin-4 (Ex4) to dicyanocobinamide (Cbi), a vitamin B12-derived corrin ring with minimal blood−brain barrier penetration. Here, we evaluate Cbi-Ex4 <em>in vitro</em> and across healthy and tumor-bearing rodent models. Cbi-Ex4 retained GLP-1R agonism and improved glucose tolerance without inducing anorexia, weight loss, or malaise, in contrast to native Ex4. These findings support peripheralized GLP-1R agonism as a promising strategy to improve metabolic dysfunction in cancer without worsening malaise and cachexia.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 10","pages":"4988–4997"},"PeriodicalIF":4.9,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149093601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular PharmaceuticsPub Date : 2026-10-05Epub Date: 2026-09-23DOI: 10.1021/acs.molpharmaceut.6c00454
Jiayu Sui, Jingjie Qin, Jessica C. Hsu, Rachel J. Saladin, Todd E. Barnhart, Jonathan W. Engle, Xudong Hu, Jinming Yu, Weibo Cai, Yuchun Wei
{"title":"Preclinical Evaluation of B7−H3-Targeted ADC-Based Molecular Imaging in Lung and Triple-Negative Breast Cancer","authors":"Jiayu Sui, Jingjie Qin, Jessica C. Hsu, Rachel J. Saladin, Todd E. Barnhart, Jonathan W. Engle, Xudong Hu, Jinming Yu, Weibo Cai, Yuchun Wei","doi":"10.1021/acs.molpharmaceut.6c00454","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00454","url":null,"abstract":"<p>B7−H3 is widely expressed in multiple solid tumors but shows minimal expression in normal tissues, making it an ideal target for molecular imaging; however, its systematic investigation remains limited. In this study, we utilized the clinically investigated B7−H3-targeted antibody−drug conjugate (ADC) HS-20093 to develop and evaluate a novel immuno-positron emission tomography (immuno-PET) tracer, [<sup>89</sup>Zr]Zr-DFO-HS-20093, for accurate imaging of B7−H3 expression in lung cancer and triple-negative breast cancer models. [<sup>89</sup>Zr]Zr-DFO-HS-20093 was synthesized with high radiochemical purity (98.2 ± 0.6%). Cellular uptake assays revealed significantly higher tracer uptake in A549 cells than in 4T1 cells at 1, 2, and 4 h (all <em>P</em> < 0.0001), which was markedly reduced by blocking with excess unlabeled antibody. Immunofluorescence revealed predominant membrane localization of B7−H3 in 4T1 cells, whereas A549 cells exhibited pronounced intracellular distribution, suggesting enhanced internalization. In tumor-bearing mice, [<sup>89</sup>Zr]Zr-DFO-HS-20093 positron emission tomography (PET)/CT enabled clear tumor visualization, with peak uptake at 24 h post-injection in both A549 and 4T1 xenografts (9.63 ± 1.97 and 7.15 ± 3.14 μCi/mL, respectively), supporting its potential for tumor imaging. Ex vivo biodistribution data corroborated the PET findings, showing significantly higher tracer uptake in A549 tumors (5.01 ± 1.19 % ID/g) than in blocked tumors (2.89 ± 0.43 % ID/g) and 4T1 tumors (1.89 ± 0.47 % ID/g) (<em>P</em> = 0.034 and <em>P</em> = 0.003, respectively). Immunohistochemical analysis of A549 xenografts showed strong B7−H3 expression (3+), whereas 4T1 tumors exhibited lower expression levels (1−2+), further confirming that B7−H3 expression patterns were consistent with the imaging results. [<sup>89</sup>Zr]Zr-DFO-HS-20093 enables sensitive immuno-PET imaging of B7−H3 and reveals tumor-type-dependent differences in B7−H3 expression and intracellular behavior.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 10","pages":"4884–4892"},"PeriodicalIF":4.9,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149093570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Self-Assembled Affibody-Drug Conjugate Nanoagent for EGFR-Targeted Synergistic Codelivery of Exatecan and an MDM2 Inhibitory Peptide","authors":"Mengqiao Zhao, Wenhui Gao, Xuelin Xia, Xiao-Xia Xia, Zhi-Gang Qian","doi":"10.1021/acs.molpharmaceut.6c00580","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00580","url":null,"abstract":"<p>Regulation of the tumor suppressor p53 is a promising approach for cancer treatment; however, a single regulatory method often shows limited efficacy. Here, we develop an affibody-drug conjugate nanoagent (ADCN) for the targeted codelivery of topoisomerase I inhibitor DX8591 and p53-MDM2 inhibitor PMI to upregulate p53 levels in cancer cells. The tripartite conjugate Z<sub>EGFR:1907</sub>-PMI-DX8591 self-assembled into nanoparticles with an average diameter of 74.4 nm, resulting in improved pharmacokinetic profiles and enhanced tumor-targeting ability. After efficient EGFR-mediated cellular uptake, the Z<sub>EGFR:1907</sub>-PMI-DX8591 ADCN released DX8591 and PMI intracellularly, leading to synergistic p53 activation by inducing p53 production and blocking its degradation. In EGFR-positive non-small cell lung tumor models, the ADCN showed excellent tumor accumulation and achieved 81.7% tumor growth inhibition, which was 1.5-fold and 1.2-fold higher than those of the Z<sub>EGFR:1907</sub>-PMI and Z<sub>EGFR:1907</sub>-DX8591 monotherapies, respectively. This affibody-based delivery system provides a promising strategy for synergistic cancer therapy.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 10","pages":"4974–4987"},"PeriodicalIF":4.9,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149093654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular PharmaceuticsPub Date : 2026-10-05Epub Date: 2026-09-04DOI: 10.1021/acs.molpharmaceut.6c00526
Katherine Vaidya, Senjuti Karmaker, Natalie Boehnke, Samira M. Azarin
{"title":"Modular Chemical Barcodes Enable Pooled Screening of Multimaterial Nanoparticle Libraries via GC−MS Quantitation","authors":"Katherine Vaidya, Senjuti Karmaker, Natalie Boehnke, Samira M. Azarin","doi":"10.1021/acs.molpharmaceut.6c00526","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00526","url":null,"abstract":"<p>Nanoparticle barcoding is a powerful approach to accelerate preclinical screening of nanotherapeutics by enabling rapid collection of high-volume data using fewer biological resources, with reduced experimental labor and fewer confounding variables across experiments. We previously introduced aryl halide-based tags (halocodes) as a barcoding technology with sensitive gas chromatography−mass spectrometry (GC−MS) detection, enabling nanoparticle tracking with minimal halocode incorporation and without measurably altering nanoparticle physicochemical properties. Building on this foundation, in this work, we developed a next generation of alkoxy-modified halocodes with tunable chemical properties that enhance encapsulation and stability within nanomaterials and extend the halocoding platform to lipid-based systems. By systematically varying halocode chemical structure and nanoparticle synthesis parameters, we established design rules governing halocode loading and retention in both polymeric nanoparticles and liposomes. We then leveraged next generation halocodes to perform a pooled in vitro screen of a mixed-core PLGA and liposomal-based nanoparticle library to identify nanoparticle core and surface chemistries with the highest affinity for ovarian cancer cells. Together, next generation halocodes provide a more modular and broadly compatible barcoding toolkit that simplifies pooled screening and supports quantitative evaluation of diverse nanocarrier libraries across biological settings.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 10","pages":"4935–4948"},"PeriodicalIF":4.9,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149124648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular PharmaceuticsPub Date : 2026-10-05Epub Date: 2026-09-02DOI: 10.1021/acs.molpharmaceut.6c00470
Anna Schildt, Malena Beecken, Tobias Lindner, Markus Joksch, Jens Kurth, Marc-André Weber, Brigitte Vollmar, Bernd J. Krause, Sarah Joost
{"title":"Low Uptake of [18F]Flutemetamol in the Mouse Brain Prevents Non-invasive Quantification of Myelin","authors":"Anna Schildt, Malena Beecken, Tobias Lindner, Markus Joksch, Jens Kurth, Marc-André Weber, Brigitte Vollmar, Bernd J. Krause, Sarah Joost","doi":"10.1021/acs.molpharmaceut.6c00470","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00470","url":null,"abstract":"<p>Direct in vivo imaging of myelin would greatly benefit research on demyelinating diseases such as multiple sclerosis but remains technically challenging. This study evaluated whether the amyloid-β radiotracer [<sup>18</sup>F]Flutemetamol is suitable for PET/CT imaging of myelin in the murine cuprizone model of demyelination. Male C57BL/6 mice were fed 0.3% cuprizone for five weeks (<em>n</em> = 5) or control chow (<em>n</em> = 5) and subsequently underwent a 90 min dynamic [<sup>18</sup>F]Flutemetamol PET/CT scan with a retest scan two days later. PET data were analyzed using region-of-interest-based quantification with an image-derived input function; volume of distribution (<em>V</em><sub>T</sub>) was estimated by Logan graphical analysis, and percentage injected dose per milliliter (% ID/mL) was calculated as a simplified uptake measure. Demyelination was independently validated by MRI and histology. Cuprizone treatment induced significant body weight loss and robust region-specific demyelination of the corpus callosum, confirmed by reduced myelin marker expression, increased astroglial and microglial activation, and corresponding MRI changes. In contrast, in vivo [<sup>18</sup>F]Flutemetamol PET showed rapid radiotracer washout, low brain retention, and high variability. Estimated <em>V</em><sub>T</sub> values were very low and did not differ between control and cuprizone-treated mice. Similarly, % ID/mL failed to detect group differences in any analyzed brain region and showed high test−retest variability. Despite histologically confirmed demyelination and corresponding T2-weighted MRI signal alterations, [<sup>18</sup>F]Flutemetamol PET/CT did not provide sufficient sensitivity or quantitative robustness to detect myelin loss in vivo. This negative finding might reflect a combination of tracer-related and methodological limitations, including limited spatial resolution and uncertainties in quantitative modeling, and therefore does not allow a definitive conclusion regarding the intrinsic suitability of [<sup>18</sup>F]Flutemetamol for preclinical myelin imaging.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 10","pages":"4893–4903"},"PeriodicalIF":4.9,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149124652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"First-In-Human PET Imaging of Synaptic Vesicle Glycoprotein 2A with [18F]BIBD-181: Automation, Biodistribution, Dosimetry, and Preliminary Application in Epilepsy","authors":"Zhen Qiao, Shen Li, Yongzhong Zhang, Xiaobin Zhao, Zihao Yang, Xinyu Sun, Hualong Chen, Xuebo Cheng, Yajing Liu, Lin Ai, Zehui Wu","doi":"10.1021/acs.molpharmaceut.6c01052","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c01052","url":null,"abstract":"<p>We report the first-in-human evaluation of [<sup>18</sup>F]BIBD-181, a novel SV2A tracer designed with a fluoropropyl side chain to enable mild, automated radiosynthesis. A fully automated cGMP-compliant production process was developed on a commercial synthesizer, yielding the tracer with >95% radiochemical purity and molar activity >130 GBq/μmol. In eight healthy volunteers, [<sup>18</sup>F]BIBD-181 demonstrated excellent safety, rapid brain penetration peaking at 15 s post-injection, and a regional uptake pattern consistent with known synaptic vesicle glycoprotein 2A (SV2A) distribution (pallidum SUV = 2.01 ± 0.57 at 30 min). The effective dose was 2.7 μSv/MBq, with predominant renal clearance and no detectable defluorination. In pilot epilepsy patients, [<sup>18</sup>F]BIBD-181 positron emission tomography (PET) results revealed focal SV2A reductions that were confined to the epileptogenic lesions<span></span>a sclerotic hippocampus in one patient and a focal cortical dysplasia (FCD) in another<span></span>whereas [<sup>18</sup>F]FDG showed either extensive ipsilateral temporal hypometabolism or concordant focal hypometabolism, suggesting that SV2A imaging may offer more precise lesion delineation, particularly when [<sup>18</sup>F]FDG abnormalities extend beyond the true epileptogenic zone. These findings establish [<sup>18</sup>F]BIBD-181 as a clinically practical SV2A PET tracer with favorable dosimetry, simplified production, and promising utility for epilepsy surgical planning, warranting further validation in larger cohorts.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 10","pages":"5151–5160"},"PeriodicalIF":4.9,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149124923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Macropa-Based 225Ac-Labeled RGD Peptides for Targeted Alpha Therapy","authors":"Hiroaki Echigo, Masayuki Munekane, Takeshi Fuchigami, Kenji Mishiro, Hidetoshi Kikunaga, Kazuaki Tsukada, Takuya Yokokita, Kenji Shirasaki, Jun Ichinose, Eiichi Hinoi, Seigo Kinuya, Kazuma Ogawa","doi":"10.1021/acs.molpharmaceut.6c00344","DOIUrl":"10.1021/acs.molpharmaceut.6c00344","url":null,"abstract":"<p>Macropa has formed more stable complexes with <sup>225</sup>Ac,although DOTA has been extensively used as a chelator for <sup>225</sup>Ac. This study aimed to design and synthesize two novel <sup>225</sup>Ac-labeled RGD peptides, [<sup>225</sup>Ac]Ac-Macropa-c(RGDyK) ([<sup>225</sup>Ac]<strong>1</strong>) and [<sup>225</sup>Ac]Ac-Macropa-[c(RGDyK)]<sub>2</sub> ([<sup>225</sup>Ac]<strong>2</strong>), and to evaluate theirpotential for targeted alpha therapy (TAT) of glioblastoma. Further,whether combination therapy with homoarginine (hArg), a modulatorof lysosomal function, could further improve therapeutic efficacywas investigated. In Colon-26 cells, [<sup>225</sup>Ac]<strong>2</strong> demonstrated significantly higher cellular uptake and cytotoxicitythan [<sup>225</sup>Ac]<strong>1</strong>. In Colon-26 tumor-bearing mice,[<sup>225</sup>Ac]<strong>2</strong> exhibited higher tumor accumulationand significant tumor growth inhibition. In GL261 glioblastoma cells,[<sup>225</sup>Ac]<strong>2</strong> showed comparable cellular uptaketo that in Colon-26 cells, and combination with hArg in vitro improvedits cytotoxicity. However, no significant difference in therapeuticefficacy was observed between the hArg-treated and control groupsin the orthotopic GL261 glioblastoma mouse model. The results of thisstudy indicate the potential of <sup>225</sup>Ac-labeled RGD peptidesincorporating Macropa as a chelator as promising agents for TAT. However,the further optimization of combination strategies and pharmacokineticsis required.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 9","pages":"4611–4621"},"PeriodicalIF":4.9,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148672723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular PharmaceuticsPub Date : 2026-09-07Epub Date: 2026-07-28DOI: 10.1021/acs.molpharmaceut.6c00683
Emma Larsson, Moeen Ud-din, Athanasios Bitzios, Enrique Recasens Pérez-Vera, Hanna Tegel, Anna Orlova, Vladimir Tolmachev, Anzhelika Vorobyeva, Sophia Hober
{"title":"Integrating Tumor Targeting and Half-Life Extension into a Dual-Surfaced Single-Domain ADAPT Protein","authors":"Emma Larsson, Moeen Ud-din, Athanasios Bitzios, Enrique Recasens Pérez-Vera, Hanna Tegel, Anna Orlova, Vladimir Tolmachev, Anzhelika Vorobyeva, Sophia Hober","doi":"10.1021/acs.molpharmaceut.6c00683","DOIUrl":"10.1021/acs.molpharmaceut.6c00683","url":null,"abstract":"<p>Folate receptor alpha(FRα) is frequently overexpressedinovarian cancer while showing limited expression in healthy tissues.Targeting of FRα has been extensively investigated using antibody-basedtherapies but less so with small scaffold proteins. Small scaffoldproteins represent an alternative approach with potential advantagessuch as site-specific conjugation and deep tumor penetration but arelimited by a short half-life. Here, we describe the development ofa dual-surfaced ADAPT scaffold protein (6 kDa) with simultaneous bispecificityfor FRα and albumin. Using combinatorial libraries and phagedisplay, we identified a candidate, termed ADAPT22, with high isoformselectivity and subnanomolar affinity for FRα (<em>K</em><sub>D</sub> = 0.8 nM), paired with a low nanomolar affinity foralbumin (<em>K</em><sub>D</sub> = 2.4 nM). Importantly, ADAPT22is able to interact with both targets simultaneously, truly combiningextended retention in blood via albumin association and tumor targetingvia FRα within a single-domain protein. The simultaneous naturewas verified <em>in vitro</em> to soluble proteins and toFRα-positive cells and <em>in vivo</em> using a mousexenograft model. In mice, ADAPT22 demonstrated markedly extended bloodretention, reduced renal uptake, and specific accumulation in FRα-positivetumors, confirming simultaneous dual-surface binding. To the bestof our knowledge, this is the smallest half-life extended affinityprotein designed for therapeutic targeting of FRα.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 9","pages":"4743–4757"},"PeriodicalIF":4.9,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148899744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular PharmaceuticsPub Date : 2026-09-07Epub Date: 2026-07-31DOI: 10.1021/acs.molpharmaceut.6c00458
Justyna Knapik-Kowalczuk, Abu T. M. Serajuddin, Paulina Poloczek, Mariya Mathew, Julia Cichocka-Łokuciejewska, Marian Paluch
{"title":"Eutectic Itraconazole and Posaconazole System and the Advantages of Its Use in the Amorphous Form","authors":"Justyna Knapik-Kowalczuk, Abu T. M. Serajuddin, Paulina Poloczek, Mariya Mathew, Julia Cichocka-Łokuciejewska, Marian Paluch","doi":"10.1021/acs.molpharmaceut.6c00458","DOIUrl":"10.1021/acs.molpharmaceut.6c00458","url":null,"abstract":"<p>Itraconazole (ITR)and posaconazole (POS) exhibit closely relatedmolecular structures but differ significantly in their ability toform liquid crystalline (LC) phases. This makes them an attractivemodel system to investigate how subtle structural differences influencemolecular organization in the amorphous state. In this work, we investigatecoamorphous systems composed of ITR and POS prepared via melt-quenching,focusing on the interplay between molecular dynamics, physical stability,and LC ordering. Differential scanning calorimetry (DSC) and broadbanddielectric spectroscopy (BDS) reveal that the glass transition temperatureremains nearly unchanged over a wide compositional range, indicatingcomparable molecular mobility of all investigated systems. Despitethis similarity, a pronounced, nonmonotonic dependence of crystallizationkinetics on composition is observed, with a clear stability maximumat the eutectic ratio. Strikingly, this specific composition is alsoassociated with the complete disappearance of the LC ordering characteristicof neat ITR. While ITR-rich mixtures close to the eutectic point stillexhibit residual LC transitions, the eutectic composition yields afully disordered amorphous phase. These results demonstrate, for thefirst time, that coamorphization at the eutectic composition mightsuppress LC ordering. The findings highlight the critical role ofcomposition in governing both molecular organization and stabilityin amorphous pharmaceuticals.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 9","pages":"4690–4701"},"PeriodicalIF":4.9,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148899751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}